Rockwell Medical, Inc. (RMTI) Q2 2026 Earnings Call Transcript
Rockwell Medical, Inc. (RMTI) Q2 2026 Earnings Call Transcript
Seeking Alpha8/13/2026Neutral
RMTI
Rockwell Medical IncNASDAQHEALTHCAREDRUG MANUFACTURERS - SPECIALTY & GENERIC
Key Statistics
Market Cap
$32.18M
P/E Ratio
—
EPS
$-1.32
Beta
1.64
52W High
$18.45
52W Low
$4.88
50-Day MA
$6.90
200-Day MA
$8.47
Dividend Yield
—
Profit Margin
-7.33%
Forward P/E
18.55
PEG Ratio
4.43
About Rockwell Medical Inc
Rockwell Medical, Inc. is a biopharmaceutical company targeting end-stage renal disease and chronic kidney disease with iron deficiency treatment and hemodialysis products and therapies in the United States and internationally. The company is headquartered in Wixom, Michigan.
Fundamentals
| Revenue (TTM) | $69.39M |
| Gross Profit (TTM) | $12.29M |
| EBITDA | $-2.43M |
| Operating Margin | -5.97% |
| Return on Equity | -15.50% |
| Return on Assets | -5.18% |
| Revenue/Share (TTM) | $17.97 |
| Book Value | $8.83 |
| Price-to-Book | 0.92 |
| Price-to-Sales (TTM) | 0.46 |
| EV/Revenue | 0.307 |
| EV/EBITDA | 22.09 |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | 10.60% |
| Shares Outstanding | $4.03M |
| Float | $3.58M |
| % Insiders | 14.80% |
| % Institutions | 8.52% |
Historical Volatility
HV 10-Day
38.67%
HV 20-Day
51.24%
HV 30-Day
49.07%
HV 60-Day
60.97%
HV Rank
12.3%
Volatility is currently contracting
Analyst Ratings
Consensus ($20.00 target)
1
Strong Buy1
BuyLatest News
Rockwell Medical (RMTI) Reports Q2 Loss, Lags Revenue Estimates
Rockwell Medical (RMTI) came out with a quarterly loss of $0.34 per share versus the Zacks Consensus Estimate of a loss of $0.17. This compares to a loss of $0.5 per share a year ago.
Zacks Investment Research8/13/2026Negative
Rockwell Medical Announces Second Quarter 2026 Results
WIXOM, Mich.--(BUSINESS WIRE)---- $RMTI #EndStageKidneyDisease--Rockwell Medical announces Q2'26 results, delivering strong year-over-year growth, expanding gross margin and generating positive operating cash flow.
Business Wire8/13/2026Neutral
Rockwell Medical (RMTI) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release
Rockwell Medical (RMTI) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Zacks Investment Research8/6/2026Negative
Rockwell Medical Advances Quality and Regulatory Leadership
WIXOM, Mich.--(BUSINESS WIRE)---- $RMTI #EndStageKidneyDisease--Brian Cox joins Rockwell Medical as VP, Quality and Regulatory Compliance, bringing more than 20 years' healthcare experience to the Company.
Business Wire7/22/2026Neutral
Rockwell Medical Regains Compliance with Nasdaq Listing Requirements
WIXOM, Mich.--(BUSINESS WIRE)---- $RMTI #EndStageKidneyDisease--Rockwell Medical received notice from Nasdaq that it regained compliance with the minimum bid price requirement under Nasdaq Listing Rule 5550(a)(2).
Business Wire7/20/2026Neutral
Rockwell Medical to Release Second Quarter 2026 Results on Thursday, August 13, 2026
WIXOM, Mich.--(BUSINESS WIRE)---- $RMTI #EndStageKidneyDisease--Rockwell Medical will release its results for the second quarter ended June 30, 2026 on Thursday, August 13, 2026.
Business Wire7/16/2026Neutral
Rockwell Medical Announces 1-for-10 Reverse Stock Split
WIXOM, Mich.--(BUSINESS WIRE)---- $RMTI #EndStageKidneyDisease--Rockwell Medical's Board of Directors has authorized a 1-for-10 reverse split of the Company's issued and outstanding common stock.
Business Wire6/29/2026Neutral
Rockwell Medical Renews Product Purchase Agreement with aQua Dialysis
WIXOM, Mich.--(BUSINESS WIRE)---- $RMTI #EndStageKidneyDisease--Rockwell Medical will supply aQua Dialysis with liquid and dry, acid and bicarbonate hemodialysis concentrates and other essential dialysis products.
Business Wire5/20/2026Neutral
Rockwell Medical Signs New 3-Year Product Purchase Agreement with Heritage Dialysis
WIXOM, Mich.--(BUSINESS WIRE)---- $RMTI #EndStageKidneyDisease--Rockwell Medical will supply Heritage Dialysis with a portfolio of hemodialysis products including PureCart, RenalPure, SteriLyte and other products.
Business Wire5/14/2026Neutral
Turn research into an automated options-selling system
Tiblio connects your broker and runs your put-and-call-writing strategy for you — on RMTI and any ticker you trade — then tracks every position and per-strategy win rate.
More HEALTHCARE Stocks
Data last updated: 9/7/2026